Ischemic Stroke, Stable Angina Pectoris of Coronary Heart Disease
Conditions
Interventions
Treatment group:Oral Rendongteng Decoction
Control Group:Oral Placebo Granules
Sponsors
Beijing University of Chinese Medicine Dongzhimen Hospital
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Ischemic Stroke Meet diagnostic criteria for ischemic stroke; 2) TCM syndrome differentiation confirming intermingled stasis and toxin; 3) hs-CRP =1.5mg/L; 4) NIHSS score 2-22; 5) Age 40-80 years, any gender; 6) Voluntary participation with signed informed consent. 2. Stable Angina Pectoris of Coronary Heart Disease 1) Meet diagnostic criteria for stable angina pectoris; 2) TCM syndrome differentiation confirming intermingled stasis and toxin; 3) hs-CRP =1.5mg/L; 4) CCS angina classification I-III, including asymptomatic, stable exertional angina, other types of angina, or ACS stabilized for >1 month; 5) Age 40-80 years, any gender; 6) Voluntary participation with signed informed consent. Note: For patients meeting both disease criteria, group assignment based on most recent diagnosis.
Exclusion criteria
Exclusion criteria: 1) Ischemic Stroke: 1)Stroke caused by brain tumor, trauma, or hematologic disease; 2) Comorbid conditions affecting limb function (e.g., claudication, osteoarthritis, rheumatoid arthritis, gouty arthritis) interfering with neurological examination; 3) Severe arrhythmia, atrial fibrillation, or heart failure; 4) Poorly controlled hypertension (SBP >160mmHg and/or DBP >100mmHg); severe airway dysfunction requiring intubation/ventilation. 2) Stable Angina Pectoris: 1) Recent myocardial infarction (160mmHg and/or DBP >100mmHg); 5) Prophylactic nitrate use within 7 days pre-screening for angina relief (e.g., isosorbide mononitrate, isosorbide dinitrate) unwilling to discontinue during non-episode periods. 3) Others: 1) Severe hepatic/renal/hematopoietic/endocrine/respiratory disorders (liver enzymes >1.5×ULN, Cr >normal, platelets <normal); 2) Allergic constitution or known allergy to trial drugs; 3) Pregnant/lactating women or those planning pregnancy; 4) Active ulcers/bleeding tendency, long-term anticoagulant use (e.g., warfarin); 5) Current antibiotic use; 6) Life-threatening conditions affecting follow-up; 7) Other diseases limiting efficacy evaluation; 8) Participation in other drug trials within 4 weeks.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Hs-CRP; | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in Syndrome Score of Intermingled Stasis and Toxin;IL-6;IL-1ß;NIHSS Scale;VAS Score for Typical Symptoms;Reduction/Discontinuation Rate of Emergency Medications; | — |
Countries
China
Contacts
Public ContactWu Shengxian
Beijing University of Chinese Medicine Dongzhimen Hospital
Outcome results
None listed